Caption Management’s Soleno Therapeutics SLNO Stock Holding History

Caption Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$2.31M	–	2021
2025 Q4	$2.31M	Hold	50,000	–	–	0.02%	788
2025 Q3	$3.38M	Sell	50,000 -47,100	-49%	-$3.49M	0.03%	633
2025 Q2	$8.14M	Sell	97,100 -530,900	-85%	-$39.7M	0.09%	266
2025 Q1	$44.9M	Sell	628,000 -148,300	-19%	-$7.22M	0.43%	41
2024 Q4	$34.9M	Buy	776,300 +569,000	+274%	+$29.5M	0.33%	44
2024 Q3	$10.5M	Buy	+207,300	New	+$9.92M	0.17%	146
2020 Q3	–	Sell	-28,200	Closed	-$939K	–	1234
2020 Q2	$939K	Buy	+28,200	New	+$1.22M	0.03%	547

Caption Management's SLNO Position: Q2 2026 in Review

Caption Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 420,143 shares — an estimated $14.1M sold.

Caption Management first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $25M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Caption Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Caption Management sold 420,143 Soleno Therapeutics shares in Q2 2026, an estimated $14.1M.
Caption Management first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
Caption Management's Soleno Therapeutics position peaked at $25M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.